Rocket Pharmaceuticals received FDA approval for Kresladi (gene therapy) for leukocyte-adhesion deficiency type 1 (LAD-1), an ultra-rare, potentially fatal inherited immunodeficiency in infants and young children. The approval positions Kresladi as the first commercial Rocket product and the first gene therapy indicated for LAD-1. The decision highlights the continued expansion of gene therapy into ultra-rare immune disorders where treatment options remain limited and outcomes are particularly time-sensitive. It also adds momentum for the company’s broader platform strategy centered on gene transfer technologies.